259809-44-4

Usage

Uses

Used in Pharmaceutical Research and Development:
TERT-BUTYL 7,8-DIHYDRO-1,6-NAPHTHYRIDINE-6(5H)-CARBOXYLATE is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential therapeutic effects. Its unique chemical structure allows for the development of new drugs with specific target actions in the treatment of various diseases.
Used in Organic Chemistry:
In the field of organic chemistry, TERT-BUTYL 7,8-DIHYDRO-1,6-NAPHTHYRIDINE-6(5H)-CARBOXYLATE is used as a reagent or building block for the synthesis of novel chemical compounds. Its properties make it suitable for creating complex organic molecules with specific functions and applications.
Used in Medicinal Chemistry:
TERT-BUTYL 7,8-DIHYDRO-1,6-NAPHTHYRIDINE-6(5H)-CARBOXYLATE is utilized as a precursor in the design and synthesis of new medicinal agents. Its structural features contribute to the development of compounds with improved pharmacological profiles, such as enhanced potency, selectivity, and reduced side effects.
Used in Industrial Applications:
Although primarily focused on pharmaceutical and chemical research, TERT-BUTYL 7,8-DIHYDRO-1,6-NAPHTHYRIDINE-6(5H)-CARBOXYLATE may also find uses in other industries where novel chemical compounds are required for specific purposes, such as materials science or environmental chemistry.
Further studies and experiments are being conducted to explore the potential applications and benefits of TERT-BUTYL 7,8-DIHYDRO-1,6-NAPHTHYRIDINE-6(5H)-CARBOXYLATE, indicating its importance and relevance in the scientific community.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 80957-68-2 5,6,7,8-tetrahydro-1,6-naphthyridine 
• 75510-02-0 6-benzyl-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 65719-09-7 methyl 2-methylnicotinate 
• 155058-02-9 7,8-Dihydro-1,6-Naphthyridine-5(6H)-one 
• 116986-08-4 methyl 2-(bromomethyl)pyridine-3-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 2450-71-7 Propargylamine 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1036381-91-5 tert‐butyl 2‐oxo‐1,5,7,8‐tetrahydro‐1,6‐naphthyridine‐6(2H)‐carboxylate 
• 616875-90-2 tert-butyl octahydro-1,6-naphthyridine-6(2H)carboxylate 
• 259809-49-9 6-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylic acid 
• 259809-47-7 6-(tert-butoxycarbonyl)-2-methoxycarbonyl-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 259809-46-6 6-(tert-butoxycarbonyl)-2-cyano-5,6,7,8-tetrahydro-1,6-naphthyridine 

Relevant academic research and scientific papers

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

Cu-Catalyzed Pyridine Synthesis via Oxidative Annulation of Cyclic Ketones with Propargylamine

A Cu-catalyzed, easily scalable one-pot synthesis of fused pyridines by the reaction of cyclic ketones with propargylamine is described. The protocol was optimized based on the results of more than 30 experiments. The highest product yields were achieved in i-PrOH as a solvent in the presence of 5.0 mol % CuCl2 in air. In contrast to the well-known Au-catalyzed protocol, our procedure is "laboratory friendly", cost-effective, and suitable for preparing dozens of grams of fused pyridine-based building blocks and does not require a high-pressure autoclave technique. Decreasing the catalyst amount in the reaction to 1.25 mol % CuCl2 provided a yield comparable to that achieved with 5 mol % catalyst, though a longer reaction time was required. A plausible reaction mechanism was proposed. The scope and limitation of the reaction were studied using 24 different cyclic ketones as starting materials. The fused pyridine yield decreased among cyclic ketones in the following order: six-membered ? eight-membered > five-membered ～seven-membered. The elaborated reaction conditions demonstrated tolerance to a number of protective functional groups in ketone such as ester, tert-butoxycarbonyl (Boc)-protected amine, and acetal moieties.

PIPERIDINE UREAS AS CATHEPSIN CYSTEINE PROTEASE INHIBITORS

The present invention relates to substituted piperidine urea derivatives that are inhibitors of cathepsin K proteases and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of these enzymes. In addition, the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of bone diseases such as osteoporosis and osteoarthritis as well as other diseases and conditions. The compounds have the general formula: [Formula should be inserted here]

SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS

The present invention relates to substituted tetrahydronaphthyridine (THN) compounds of the formula (I) and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity.

Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element

Our exploratory study was based on the concept that a non-amidine factor Xa (fXa) inhibitor is suitable for an orally available anticoagulant. We synthesized and evaluated a series of N-(6-chloronaphthalen-2-yl) sulfonylpiperazine derivatives incorporating various fused-bicyclic rings containing an aliphatic amine expected to be S4 binding element. Among this series, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine type 61 displayed orally potent anti-fXa activity and evident prolongation of prothrombin time (PT) with the moderate bioavailability in rats. The X-ray crystal analysis afforded an obvious binding mode that 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine and 6-chloronaphthalene respectively bound to S4 and S1 subsites. In this X-ray study, we discovered a novel intramolecular S-O close contact. Ab initio energy calculations of model compounds deduced that conformers with the most close S-O proximity were most stable. The Mulliken population analysis proposed that this energy profile was caused by both of electrostatic S-O affinity and N-O repulsion. The results of these calculations and X-ray analysis suggested a possibility that the restricted conformation effected the affinity to S4 subsite of fXa.